Trial Profile

A Phase III study of surufatinib in combination with TUOYI in esophageal cancer

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 08 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Surufatinib (Primary) ; Toripalimab (Primary)
Indications Oesophageal cancer
Focus Therapeutic Use
Acronyms SURTORI-02

Most Recent Events

08 Mar 2022 New trial record
03 Mar 2022 According to HUTCHMED media release, the company plans to initiate SURTORI-02, a Phase III study of surufatinib in combination with TUOYI in esophageal cancer in China in the second half of 2022

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com